FDA accepts Outlook Therapeutics’ BLA for wet AMD treatment
Pharmaceutical Technology
OCTOBER 31, 2022
On receiving approval, the treatment is expected to replace the requirement to use unapproved repackaged oncologic IV bevacizumab from compounding pharmacies for wet AMD treatment. It is also developing registration documents for approvals in Europe, with submission expected in the fourth quarter of this year.
59 
Let's personalize your content